FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* BENNETT C FRANK					2. Issuer Name and Ticker or Trading Symbol ISIS PHARMACEUTICALS INC [ ISIS ]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner							
	S PHARMA	CEUTICALS, I	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 01/01/2015								below)	(give title /P, Antisense		Other (s below) Research	specify		
2855 GAZELLE COURT							4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable					
(Street) CARLSBAD CA 92010						, (							Line	1 0 11						
(City)	(S	tate)	(Zip)																	
		Tal	ole I - No	on-Der	ivativ	e Se	curitie	s Ac	quired	, Di	sposed o	f, or Ber	neficiall	y Owned						
1. Title of Security (Instr. 3)  2. Transact Date (Month/Day						Execution Date,		Code (Instr.			s Acquired (A) or f (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)			
									Code	v	Amount	(A) or (D)	Price	Transaci (Instr. 3	ction(s)			(30. 4)		
Common Stock 01/01/2			1/2015	01/01/2015		J <sup>(1)</sup>	V	136	A	\$30.047	5 4,	763		D						
			Table II								oosed of, convertib			Owned						
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Date,	4. Transa Code ( 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficial Owned Following Reported Transaction (Instr. 4)	e S Illy	Ownershi Form: Direct (D) or Indirec (I) (Instr. 4	Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exercisa	ble	Expiration Date	Title	Amount or Number of Shares							
Employee Stock Option (right to buy)	\$61.57	01/02/2015	01/02/2	01/02/2015			31,457		01/02/20:	16 <sup>(2)</sup>	01/01/2022	Common Stock	31,457	\$0	31,45	7	D			

## **Explanation of Responses:**

- 1. Reporting 136 shares acquired under the Isis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on January 1, 2015. These 136 shares may not be sold until July 2, 2015.
- 2. Grant of 1/2/2015 to reporting person of stock options under the Isis Pharmacueticals, Inc. 2011 Equity Incentive Plan. 25% of the shares subject to the option vest and become exercisable on 1/2/2016. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments, at the rate of 7,865 shares per year. The option was exercisable as to 0 on 1/2/2015.

## Remarks:

/s/C. Frank Bennett

01/05/2015

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.